Adagio Medical (ADGM) Expected to Post Earnings on Wednesday

Adagio Medical (NASDAQ:ADGM – Get Free Report) is expected to issue its Q3 2026 results before the market opens on Wednesday, November 11th. Analysts expect Adagio Medical to post earnings of ($0.30) per share for the quarter. Parties can find conference call details on the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Wednesday, November 18, 2026 at 9:30 AM ET.

Adagio Medical (NASDAQ:ADGM – Get Free Report) last posted its quarterly earnings data on Tuesday, August 11th. The company reported ($0.30) EPS for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.03). On average, analysts expect Adagio Medical to post ($1.25) EPS for the current fiscal year and ($1.75) EPS for the next fiscal year.

Adagio Medical Stock Performance

Shares of ADGM opened at $1.92 on Tuesday. Adagio Medical has a one year low of $1.55 and a one year high of $50.70. The company has a 50-day moving average of $0.29 and a two-hundred day moving average of $0.74. The stock has a market cap of $52.68 million, a price-to-earnings ratio of -1.30 and a beta of 0.07. The company has a debt-to-equity ratio of 4.00, a current ratio of 1.41 and a quick ratio of 1.15.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings lowered shares of Adagio Medical from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, August 19th. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Adagio Medical presently has a consensus rating of “Hold” and an average target price of $3.50.

Read Our Latest Stock Report on ADGM

Adagio Medical Company Profile

(Get Free Report)

Adagio Medical, Inc is a medical technology company focused on developing catheter-based treatments for cardiac arrhythmias, including atrial fibrillation. The company’s technology is designed to create continuous, transmural lesions in cardiac tissue to isolate abnormal electrical signals and help restore a normal heart rhythm.

Its lead platform is the Intelligent Continuous Lesion Ablation System (iCLAS), an ultra-low-temperature cryoablation system intended to treat atrial fibrillation and other heart rhythm disorders.

Further Reading

Earnings History for Adagio Medical (NASDAQ:ADGM)

Receive News & Ratings for Adagio Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adagio Medical and related companies with MarketBeat.com's FREE daily email newsletter.